In Brief: Guidant
This article was originally published in The Gray Sheet
Executive Summary
Guidant: Commences clinical trial of its coronary intravascular radiotherapy system for reduction of restenosis following interventional cardiology procedures Oct. 28 at the Methodist Hospital of Baylor College in Houston, Texas. Guidant received investigational device exemption approval in September to begin the PREVENT trial (Proliferation Reduction with Vascular Energy Trial), which will also take place at the Thoraxcentre in Rotterdam, The Netherlands and the Northern General Hospital in Sheffield, U.K. The radiotherapy system consists of a flexible source wire with a radioactive isotope in its tip, a source delivery unit and a centering catheter, through which the source wire is placed...
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.